The results suggested that overexpression of CXCL6 contributed to tumor growth and pulmonary metastasis via activating PI3K/AKT and Wnt/β-catenin pathways, which could be repressed by treatment with CXCR2 antagonist SB225002. The gene discussed is CXCR2; the disease is neoplasm.